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Pancreastatin activates protein kinase C by stimulating the formation of
1,2-diacylglycerol in rat hepatocytes
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Departamento de Bioqufmica Medica y Biologfa Molecular, Hospital Universitario Virgen Macarena, Facultad de Medicina, Universidad de Sevilla, 41009 Sevilla, Spain
We describe here the stimulation by pancreastatin of 1,2-
diacylglycerol production and protein kinase C activity in liver
plasma membrane and isolated hepatocytes. The dose-depen-
dency for the stimulation of both processes was similar to the
recently described pattern of glucose output and cytosolic Ca2+
transients produced by pancreastatin. The time course of diacyl-
glycerol production at 30 °C showed a rapid increase within
5 min, reaching a maximum at 10 min. Protein kinase C from
hepatocytes was dependent on Ca2+ and phosphatidylserine.
Neither the pancreastatin-stimulated diacylglycerol production
nor the activation of protein kinase C was affected by pre-
INTRODUCTION
Pancreastatin is a 49-amino-acid peptide, initially isolated from
pig pancreatic tissue [1], which was first shown to have an
inhibitory effect on insulin secretion [1-3], but whose physio-
logical role, especially in humans, is not completely understood.
However, a role as a regulatory pancreatic hormone has been
established in the light of a variety of biological effects which
could be assigned to the C-terminal part of the molecule (for
review see [4]). We have reported the glycogenolytic effect of
pancreastatin in the rat [5-7]. That effect was found to be
dependent on Ca2+ and independent of cyclic AMP [7]. The
hydrolysis of phosphatidylinositol 4,5-bisphosphate by Ca2+-
mobilizing hormones represents a bifurcation in the signal
pathway in that it results in the formation of two separate second
messengers, i.e. Ins(1,4,5)P3 and diacylglycerol (DAG) [8]. The
primary function of InsP3 is to mobilize Ca2+ from intracellular
stores [9,10], whereas DAG stimulates protein kinase C (PKC)
[11,12].
We have recently shown the increase in cytosolic free [Ca2+]
([Ca2+]1) which may be responsible for the triggering of the
glycogenolytic response to pancreastatin in isolated hepatocytes
by a process which appears to involve both pertussis-toxin-
sensitive and -insensitive mechanisms [13]. In the present work,
we studied the production of DAG from rat liver membranes in
response to pancreastatin and the influence of GTP. We used
pertussis toxin to seek a mediation of the effect by a pertussis-
toxin-sensitive mechanism. Moreover, the activity of PKC in
response to pancreastatin has been determined in isolated rat
hepatocytes.
MATERIALS AND METHODS
Chemicals
Rat pancreastatin was provided by Peninsula Laboratories
Europe (Merseyside, U.K.). [Arg]-vasopressin, 3-isobutyl-1-
treatment with pertussis toxin. However, the presence of GTP
partially inhibited this pancreastatin stimulation of 1,2-
diacylglycerol in a dose-dependent manner, although GTP alone
stimulates diacylglycerol accumulation. This inhibitory effect of
GTP on pancreastatin stimulation of diacylglycerol synthesis
was completely abolished by the pretreatment with pertussis
toxin. In conclusion, this study provides evidence that pan-
creastatin stimulates the formation of 1,2-diacylglycerol by a
pertussis-toxin-independent mechanism, which may be respon-
sible for the pancreastatin activation of protein kinase C.
methylxanthine, creatine kinase and phosphocreatine were
from Boehringer Mannheim (Mannheim, Germany). Pertussis
toxin, bacitracin, leupeptin, dithiothreitol, BSA (fraction V),
GTP, guanosine 5'-[fiy-imido]triphosphate (p[NH]ppG), EGTA,
oc-L-phosphatidylserine and lysine-rich histone were from Sigma
(St. Louis, MO, U.S.A.). [y-32P]GTP and [oc-32P]NAD' were
purchased from New England Nuclear (Du Pont de Nemours,
Dreieich, Germany).
Isolation of hepatocytes and preparation of membranes
Isolated hepatocytes were prepared from male Wistar rats
(180-220 g) fed on a standard diet ad libitum. Hepatocytes were
prepared by perfusion of the liver with collagenase as described
previously [7]. Rat liver membranes were prepared as described
by Neville [14] up to step 11. The protein concentrations were
determined with a protein assay kit (Bio-Rad) based on the
method of Bradford [15], with BSA as standard.
Pertussis-toxin treatment of liver membranes
The treatment of membranes with thiol-preactivated pertussis
toxin was carried out as described by Ribeiro-Neto et al. [16].
The control membranes were treated in an identical manner,
except that there was no toxin present in the incubation. The
membrane suspension was then centrifuged and the pellet washed
twice and finally resuspended in Hepes buffer (20 mM, pH 7.5),
containing bacitracin (0.1 mg/ml) and leupeptin (0.1 mg/ml).
The ADP-ribosylation was assessed by testing the reverse effect
of angiotensin II on glucagon-stimulated cyclic AMP production
as previously described [17]. To check whether the ADP-
ribosylation of the pertussis-toxin substrate was complete, we
performed the radiolabelling by incubating for 1 h at 30 °C with
[32P]NAD+ and preactivated pertussis toxin as previously de-
scribed [16], after preincubation of the membranes for 4 h with
or without pertussis toxin.
Abbreviations used: DAG, diacylglycerol; PKC, protein kinase C; [Ca2+] ,
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cytosolic free [Ca2+]; p[NH]ppG, guanosine 5'-[,8y-imido]triphosphate.
51
52 V. Sanchez-Margalet, M. Lucas and R. Goberna
DAG assay
DAG production was assayed at 30 °C, in a final volume of
0.5 ml, containing 50 mM Hepes, pH 7.4, BSA (2 mg/ml),
bacitracin (0.2 mg/ml), leupeptin (0.1 mg/ml) and MgCl2
(5 mM). Free Ca2l concentrations were maintained at 0.5 ,tM
with Ca2+/EGTA buffers with 0.5 mM EGTA and 0.5 mM Ca2".
When GTP was present, phosphocreatine (2 mM) and creatine
kinase (0.1 mg/ml) were also added. The incubation medium was
equilibrated for 3 min at 30 'C. The assay was initiated by
addition ofmembranes (250 ,tg) and terminated with 1 ml ofHCI
(0.01 M) and 3 ml of chloroform/methanol (2:1, v/v). Then
0.06 ml of MgCl2 (0.5 %/, w/v) was added. After vigorous mixing,
the samples were centrifuged at 5000 g for 5 min. The aqueous
layer was discarded and 1 ml of chloroform was added to the
bottom layer, which was then filtered through glass wool in a
Pasteur pipette. The solvent was evaporated under N2 at room
temperature and stored at -20 'C for 24 h until the assay for
DAG analysis. Samples were assayed by the DAG kinase
described by Preiss et al. [18], with a DAG assay reagent system
from Amersham International (Amersham, Bucks., U.K.),
which only measures sn-1,2-diacylglycerol, which is the physio-
logical activator of PKC. y-[32P]ATP was used at a specific
radioactivity of 3000 Ci/mmol. [32P]Phosphatidic acid from the
samples was purified by chromatography (Amprep minicolumns,
from Amersham International). The final eluate (2 ml of
chloroform:methanol:acetic acid, 13:2:2, by vol.) was trans-
ferred to scintillation vials and 10 ml of scintillant was added
for counting in a liquid-scintillation counter (Wallac 1490).
PKC assay
Hepatocytes were incubated in Krebs-Ringer bicarbonate me-
dium as described previously [7] at 37 'C for 10 min with shaking
(60 cycles/min) and gassed with 02/C02 (19: 1) throughout the
incubation. PKC activity was assayed as phospholipid-sensitive
Ca2+-dependent phosphorylation of lysine-rich histone (Sigma)
as described previously [19], and 1,2-diolein was omitted to avoid
masking of the pancreastatin effect due to the increases in
DAG. Basal activity, measured by omission of Ca2+ and
phosphatidylserine, was subtracted from the activity measured
in samples. The enzyme fraction was obtained by sonication of
hepatocytes in Ca2+- and Mg2+-free Hanks balanced salt solution,
and centrifugation of the homogenate at 15000 g to remove
debris, nuclei and mitochondria.
RESULTS
Time- and dose-dependence of pancreastatin and GTP-stimulated
DAG production
Figure 1 shows the time course of the production of DAG from
rat liver membranes. Pancreastatin (0.1 ,tM) in the absence of
GTP caused a 3-fold stimulation of control DAG production
after incubation for 10 min. The degree of stimulation was
halved by the presence of 10 ,1M GTP, although GTP (10 ,uM)
alone increased basal DAG production 1.5-fold. The stimulatory
effect of pancreastatin was dose-dependent, as was the partial
inhibition of this effect by GTP (Figure 2). Maximal DAG
production was obtained with 0.1 /LM pancreastatin, and this
effect was inhibited by the presence of GTP (0.1-10 tM). GTP
did not modify the ED50 of pancreastatin (3 nM), but impaired
its maximal effect in a dose-dependent manner. Unlike the effect
of pancreastatin, the effect of vasopressin was enhanced by the
presence ofGTP (Table 1). The non-hydrolysable GTP analogue
p[NH]ppG produced an increase in both vasopressin- and
pancreastatin-stimulated DAG production.
Pertussis-toxin treatment of rat liver membranes
The treatment of liver membranes with pertussis toxin did not
affect the ability of either pancreastatin or vasopressin to
stimulate the production of DAG (Table 1). However, such
treatment completely abolished the inhibitory effect of GTP on
pancreastatin-stimulated DAG production. The increase in
both pancreastatin- and vasopressin-stimulated DAG production
produced by p[NH]ppG was not affected by the pretreatment
with pertussis toxin.
Autoradiography after SDS/PAGE of the liver plasma mem-
branes with [32P]NAD+ and pertussis toxin showed an ADP-
ribosylated protein of about 40 kDa (Figure 3). To examine
whether the pertussis-toxin substrate was completely ADP-
ribosylated, the membranes were pretreated with or without
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Figure 1 Time course of DAG production: effect of pancreastatin and GTP
Membranes (250 ,ug) were incubated at 30 °C as described in the Materials and methods
section in the presence of 0.5 ,uM Ca2+ to determine the production of DAG. The reaction was
started by addition of the membranes to the tubes under the following conditions: A, buffer;
A., 10 1M GTP; 0, 0.1 ,tM pancreastatin; 0, 0.1 1uM pancreastatin + 10 /1M GTP. Results
are the values of one experiment representative of three others.
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Figure 2 Concentration-dependency of pancreastatin-stimulated DAG
production and the inhibition of this effect by GTP
The production of DAG was measured as a function of pancreastatin concentration in the
absence (0) or presence of different GTP concentrations: 0, 0; 0, 0.1 ,M; Al, 1 UM; A,
10,M. Results are given as percentages of the maximal rate of production achieved at
0.1 uM pancreastatin (1440+30 pmol/mg of protein). Data are means of the three separate
experiments.
Pancreastatin stimulates diacylglycerol production
Table 1 Effect of pertussis-toxin pretreatment of liver membranes on
pancreastatin-stimulated and/or GTP-stimulated DAG producton
Membranes were pretreated with or without pertussis toxin (PT) as described in the Materials
and methods section. The incubation medium was equilibrated for 3 min at 30 °C before
addition of the agonists (PST, pancreastatin; AVP, vasopressin) and further incubated for
10 min. Data are means + S.E.M. (n = 5): a p < 0.001 versus control; b p < 0.001 versus
the same condition -PT.
DAG production (pmol/mg of protein)
Condition -PT + PT
Control
GTP (10/OM)
PST (0.1 ,pM)
PST (0.1 ,uM)+GTP (10 ,uM)
PST (0.1 ,tM) + p[NH]ppG (lO ,uM)
AVP (0.1 ,uM)
AVP (0.1 uM)+GTP (lO,uM)
AVP (0.1 uM)+p[NH]ppG (10 pM)
520 +16
880 + 1 8'
1440 +30a
200+1Oa
1520 + 38a
1100+25a
1480 + 32a
1540 + 40a
500 + 20
885+19a
1430 +35a
1400 + 32ab
1511 +36a
1108 +24a
1471 + 30a
1530 + 35a
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Figure 4 Activation of PKC by pancreastatin
The crude homogenate, prepared as described in the Materials and methods section, were
obtained from hepatocytes incubated tor 10 min in the absence (0) or the presence ot
increasing concentrations of pancreastatin (10 pm-0.1 ,M). Means+S.E.M. of four different
experiments are shown.
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Figure 3 Pertussis-toxin-cat
rat liver plasma membranes
talysed ADP-ribosylation of a 40IkDa protein In
The membranes were pretreated with pertussis toxin (lane 1) or vehicle (lane 2) and then
washed and further incubated with pertussis toxin and [32P]NAD+. The proteins were separated
by SDS/PAGE and processed by autoradiography.
pertussis toxin for 4 h and then subjected to pertussis-toxin-
catalysed ADP-ribosylation in the presence of [32P]NAD+. The
incorporation of radiolabel into 40 kDa protein almost com-
pletely disappeared after the pretreatment with pertussis toxin
(Figure 3).
Pancreastatin stimulation of PKC activity
Basal activity of PKC from incubated hepatocytes was increased
up to 10-fold by pancreastatin (Figure 4). This pancreastatin
stimulation of PKC activity was dose-dependent, with a signi-
ficant effect at 0.1 nM pancreastatin (Figure 4). The maximum
effect was observed at 10 nM pancreastatin, and half-maximal
effect was achieved at about 0.3 nM.
DISCUSSION
DAG activates PKC [12,14] and has been recognized as a second
messenger for hormones that cause inositol lipid hydrolysis
through the activation ofphospholipase C [9]. We have previously
demonstrated the role of pancreastatin as a glycogenolytic
hormone [5,6], which may exert its action by Ca2l mobilization
[7]. In fact, we have described an increase in [Ca2l], induced by
pancreastatin in isolated hepatocytes which appears to be media-
ted by pertussis-toxin-sensitive and -insensitive mechanisms [13].
In the present paper, we show the stimulatory effect of pancrea-
statin on DAG production in rat liver membranes, as well as the
activation of PKC. We have observed that the half-maximal
concentration of pancreastatin for DAG production is very
similar to that for the production of InsP3 [20], as should be
expected from the activation of phospholipase C. However, the
maximal rate of production of the DAG in response to pancrea-
statin was achieved at higher concentrations of the hormone
than that required for maximal activation of PKC. This may
reflect either a biological amplification between the steps of the
signalling transduction, or the saturation of PKC by DAG in
experiments in vitro with intact cells.
Pancreastatin-stimulated production ofDAG was not affected
by the pretreatment of liver membranes with pertussis toxin. This
seems not to be due to an incomplete ADP-ribosylation of the
pertussis-toxin substrate, because the membranes pretreated with
pertussis toxin could not be further ADP-ribosylated. Moreover,
this effect of pancreastatin on DAG production seems to occur
in the absence of GTP, as was observed for InsP3 production. In
fact, the effect of vasopressin on DAG production was also
observed with no GTP added to the incubation mixture. Since
GTP is known to be required for phospholipase C activation, we
assume that a nanomolar concentration of GTP may be present
in membrane preparations. But when GTP was added in the
medium, the pancreastatin-stimulated DAG production was
inhibited in a dose-dependent manner. A possible explanation is
that GTP is impairing the binding of pancreastatin to its receptor
by interacting with a G-protein. A similar result should be
expected for vasopressin; however, GTP enhanced the DAG
production induced by vasopressin. On the other hand, we have
observed the pertussis-toxin-sensitive production of cyclic GMP
upon pancreastatin stimulation [20], and a role of this cyclic
nucleotide is known to be the feedback inhibition of phosphatidyl-
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inositol hydrolysis [21]. Therefore, the negative effect of GTP on
pancreastatin stimulation ofDAG production could be mediated
by the formation of cyclic GMP. Thus, after pretreatment of
membranes with pertussis toxin, the effect of GTP is abolished.
Moreover, the non-hydrolysable analogue of GTP, p[NH]ppG,
increases pancreastatin-stimulated DAG production in a similar
way as it does the vasopressin-stimulated production of DAG,
suggesting a similar pathway for the production of DAG by
vasopressin and pancreastatin.
Since the physiological substrate of PKC in the liver has been
shown to be glycogen synthase [22,23] by a mechanism that
involves phosphorylation of the enzyme [24,25], the inhibition of
glycogen synthase may be another expected biological effect of
pancreastatin. Thus, studies of the effect of pancreastatin on
insulin-stimulated glycogen synthase have shown a potent dose-
dependent inhibition over a wide range of insulin concentration
[26].
In conclusion, the synergism ofboth limbs of the phosphatidyl-
inositol 4,5-bisphosphate signalling system, i.e. InsP3/Ca2+ and
DAG/PKC, is confirmed in the transduction of the pancreastatin
action in the hepatocyte.
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